The application of the prostatic specific membrane antigene ligand 68GA-PSMA-11 in imaging of prostatic tumors using PET/CT and PET/MRI - Initial experience with tolerance of the applied substance and imaging quality
Abstract
Aim: Early evaluation of the experience with the application of 68Ga-PSMA-11 in the relation to the tolerance and the evolution of the renal and liver laboratory tests, and in relation to the quality of imaging. Methods: The sample of 20 males was evaluated, 10 using PET/CT and 10 using PET/MRI.
The vital functions during application and than the evolution of the laboratory serum levels of urea, creatinine, AST and ALT were evaluated within one week after radiopharmaceutical applications. Results: During one-week periprocedural period after radiopharmaceutcal application, there were not noted serious adverse events, in two ptients there were elevated serum Creatinine levels above the upper treshold of normal values, in one patient also elevation of AST (previously yet elevated).
No application related changes of vital values were noted. All imaging was considered as sufficient for evaluation.
Conclusion: Early experience with the application of 68Ga-PSMA-11 shows, that it does not induce changes of vital values, but in individual cases, there could be noted the changes in renal or liver blood tests, due to the realtion with the own disease development. (C) 2018 Czech Medical Association J.E. Purkyne.
All rights reserved.